Valuation: Cynata Therapeutics Limited

Market Cap 3.41M 2.36M 2.07M 1.92M 1.76M 3.34M 225M 22.9M 8.97M 111M 8.85M 8.66M 383M P/E 2024
-5.44x
P/E 2025 -3.27x
Enterprise Value -1.64M -1.14M -997K -924K -850K -1.61M -109M -11.03M -4.32M -53.35M -4.26M -4.17M -184M EV / Sales 2024
20.2x
EV / Sales 2025 15.3x
Free-Float
76.92%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Cynata Therapeutics Limited

1 day+7.69%
1 week+7.69%
1 month-94.62%
3 months-95.25%
6 months-96.27%
Current year-95.94%
1 week 0.01
Extreme 0.013
0.02
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.011
0.44
1 year 0.01
Extreme 0.011
0.44
3 years 0.01
Extreme 0.011
0.44
5 years 0.01
Extreme 0.011
0.64
10 years 0.01
Extreme 0.011
1.87
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2021-10-10
Corporate Officer/Principal - 2024-03-31
Corporate Secretary 63 2012-05-17
Director TitleAgeSince
Chairman 65 2017-02-27
Director/Board Member - 2023-06-30
Chairman 70 2020-08-17
Date Insider Type Main position Quantity % Market Cap.
23-05-31Free

Chairman

69,767 0.0390%
23-05-31Buy

Chairman

139,534 0.0780%
23-05-31Buy 11,629 0.0065%
Change 5-day change 1-year change 3-year change Capi.($)
+7.69%+7.69%-90.67%-88.80% 2.2M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-8.57%+58.09%+124.47% 54.63B
-5.60%-2.20%+11.16%+437.37% 25.06B
-1.55%-7.66%-20.21%-17.37% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+1.87%+38.13%-26.14% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-0.81%+0.34%+24.92%+189.31% 14.2B
Average -0.83%-0.74%+35.26%+169.57% 24.16B
Weighted average by Cap. -1.81%-1.56%+48.50%+166.90%

Financials

2024 2025
Net sales 2.32M 1.6M 1.41M 1.3M 1.2M 2.27M 153M 15.56M 6.09M 75.26M 6.02M 5.88M 260M 1.89M 1.3M 1.15M 1.06M 976K 1.84M 125M 12.67M 4.96M 61.27M 4.9M 4.79M 212M
Net income -9.74M -6.74M -5.92M -5.49M -5.05M -9.54M -645M -65.47M -25.65M -317M -25.31M -24.76M -1.1B -9.39M -6.5M -5.71M -5.29M -4.86M -9.19M -621M -63.09M -24.71M -305M -24.39M -23.86M -1.06B
Net Debt -6.21M -4.29M -3.77M -3.49M -3.21M -6.07M -411M -41.69M -16.33M -202M -16.12M -15.77M -697M -5.05M -3.49M -3.07M -2.84M -2.61M -4.94M -334M -33.93M -13.29M -164M -13.12M -12.83M -568M
Logo Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.
Employees
2
Date Price Change Volume
26-07-13 A$0.0140 +7.69% 28,766
26-07-10 A$0.0130 -7.14% 659,819
26-07-09 A$0.0140 0.00% 85,729
26-07-08 A$0.0140 0.00% 151,000
26-07-07 A$0.0140 -12.50% 250,195

Annual profits - Rate of surprise